Xiangcai Wang

机构：Jiangxi Provincial Cancer Hospital, Qingzhou City People's Hospital, Gannan Medical University, Jiangxi Chest Hospital, First Affiliated Hospital of Gannan Medical University, Synergy Health · ORCID：0000-0002-7162-0552

发表论文 60 篇 · 总被引 852 次 · h-index 11

代表论文

• Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 46)
• Machine learning models for predicting metabolic dysfunction-associated steatotic liver disease prevalence using basic demographic and clinical characteristics (2025 · Journal of Translational Medicine · 被引 37)
• Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial (2025 · Clinical Cancer Research · 被引 5)
• Promising early results of MHB088C (B7-H3 ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from a phase 1/2 multicenter study. (2025 · Journal of Clinical Oncology · 被引 4)
• USP39: a key regulator in malignant tumor progression (2025 · Frontiers in Oncology · 被引 3)
• USP38: an important regulatory factor in tumor malignant progression (2025 · Frontiers in Immunology · 被引 2)